Login / Signup

Identification and Evaluation of Reversible Covalent Binders to Cys55 of Bfl-1 from a DNA-Encoded Chemical Library Screen.

Simon C C LucasJ Henry BlackwellUlf BörjessonDavid HargreavesAlexander G MilbradtSamiyah AhmedMark J BostockCarine GuerotAndrea GohlkeOlaf KinzelMichelle L LambNidhal SelmiChristopher J StubbsNancy SuQibin SuHaiou LuoTing XiongXiaoqian ZuoSana BazzazCorey BienstockPaolo A CentrellaKyle E DentonDiana GikunjuMarie-Aude GuiéJohn P GuilingerChristopher HuppAnthony D KeefeTakashi SatohYing ZhangEmma L Rivers
Published in: ACS medicinal chemistry letters (2024)
Bfl-1 is overexpressed in both hematological and solid tumors; therefore, inhibitors of Bfl-1 are highly desirable. A DNA-encoded chemical library (DEL) screen against Bfl-1 identified the first known reversible covalent small-molecule ligand for Bfl-1. The binding was validated through biophysical and biochemical techniques, which confirmed the reversible covalent mechanism of action and pointed to binding through Cys55. This represented the first identification of a cyano-acrylamide reversible covalent compound from a DEL screen and highlights further opportunities for covalent drug discovery through DEL screening. A 10-fold improvement in potency was achieved through a systematic SAR exploration of the hit. The more potent analogue compound 13 was successfully cocrystallized in Bfl-1, revealing the binding mode and providing further evidence of a covalent interaction with Cys55.
Keyphrases
  • small molecule
  • drug discovery
  • high throughput
  • dna binding
  • single cell